Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Luigi Naldini
Milan, Italy
- Ownership
- Private
- Development stage
- Other
01
Overview
Genespire's platform and pipeline focus on gene therapy approaches targeting hematopoietic stem and progenitor cells; recent work has enabled clinical translation of immune shielded lentiviral vectors and new genome editing tools for safe and durable correction of genetic blood diseases
- Therapeutic areas
- HematologyMetabolic DisordersImmunology
- Modalities
- Gene therapyLentiviral vectorGenome editing
- Industry
- Biotech
02
Partnerships
Fondazione TelethonSan Raffaele Telethon Institute for Gene Therapy (SR-TIGET)collaborations with academic groupsGenenta (spin-off for program commercialized in glioblastoma)
Beyond the preview
Go deeper on Luigi Naldini.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Luigi Naldini.